Citigroup Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals (LON:HIK) had its target price upped by analysts at Citigroup from GBX 1,700 to GBX 1,870 in a research report issued on Wednesday,Digital Look reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price points to a potential upside of 13.82% from the stock’s previous close.

HIK has been the topic of a number of other research reports. Jefferies Financial Group upped their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Finally, Berenberg Bank upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a report on Tuesday. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals has an average rating of “Buy” and an average price target of GBX 2,060.

Hikma Pharmaceuticals Trading Up 0.3%

LON:HIK opened at GBX 1,643 on Wednesday. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 1,865. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The firm’s 50 day moving average is GBX 1,542.79 and its 200 day moving average is GBX 1,454.39. The stock has a market capitalization of £3.43 billion, a PE ratio of 9.08, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66.

Insider Activity at Hikma Pharmaceuticals

In other news, insider Tobias Hestler purchased 7,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by company insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.